文献速递临床试验与 GCP基础与转化研究

多草本报食补充剂用于糖尿病前期成人:随机对照试验研究方案

Polyherbal dietary supplementation for prediabetic adults: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-01-07

本研究为多中心、双盲、随机对照试验,计划纳入40例糖尿病前期成人,随机接受每日口服多草本报食补充剂或安慰剂12周,评估其对血糖、血脂、炎症标志物及安全性的影响,旨在探索多草本报食补充剂改善糖尿病前期代谢指标的潜力。

要点

  • 多草本报食补充剂含肉桂、巴拿巴叶、葛根、胡芦巴、匙羹藤、西洋参和小檗碱。
  • 主要评估血糖控制短、中、长期标志物及血脂、炎症和安全指标。
  • 采用意向性分析评估结局变化。

核心结论

  • 该研究旨在评估市售多草本报食补充剂对糖尿病前期个体血糖和血脂参数的疗效与安全性。

研究设计与样本

  • 多中心、双盲、随机对照临床试验,计划纳入40例糖尿病前期参与者,随机分配至多草本报食补充剂组或安慰剂组,干预12周。

关键数值与推荐

  • 干预为每日口服GlucoSupreme™ Herbal(含肉桂树皮、标准化1%科罗索酸的巴拿巴叶、标准化40%异黄酮的葛根、标准化60%皂苷的胡芦巴种子、标准化25%匙羹藤酸的匙羹藤叶、标准化5%人参皂苷的西洋参根、源自小檗树皮的盐酸小檗碱)或安慰剂,持续12周。
  • 评估指标包括血糖和空腹胰岛素、果糖胺、糖化血红蛋白/ A1c、GlycoMark、β细胞功能、胰岛素敏感性/抵抗、血脂谱(总胆固醇、LDL、HDL、甘油三酯)、hs-CRP、进展为2型糖尿病以及安全性指标(ALT、AST)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prediabetes describes a state of hyperglycemia outside of normal limits that does not meet the criteria for diabetes diagnosis, is generally symptomless, and affects an estimated 38% of adults in the United States. Prediabetes typically precedes the diagnosis of type 2 diabetes, which accounts for increased morbidity and mortality. Although the use of dietary and herbal supplements is popular worldwide, and a variety of single herbal medicines have been examined for glycemic management, the potential of increasingly common polyherbal formulations to return glycemic parameters to normal ranges among adults with prediabetes remains largely unexplored. The purpose of this study is to evaluate the efficacy of a commercially available, polyherbal dietary supplement on glycemic and lipid parameters in prediabetic individuals. METHODS: In this multi-site, double-blinded, randomized controlled clinical trial, 40 participants with prediabetes will be randomized to either a daily oral polyherbal dietary supplement (GlucoSupreme™ Herbal; Designs for Health®, Suffield, CT, USA; containing cinnamon bark (Cinnamomum cassia), banaba leaf (Lagerstroemia speciosa standardized to 1% corosolic acid), kudzu root (Pueraria lobata standardized to 40% isoflavones), fenugreek seed (Trigonella foenum-graceum standardized to 60% saponins), gymnema leaf (Gymnema sylvestre standardized to 25% gymnemic acid), American ginseng root (Panax quinquefolius standardized to 5% ginsenosides), and berberine HCl derived from bark (Berberis aristata)) or placebo for 12 weeks. Short-, medium-, and comparatively long-term markers of glycemic control (blood glucose and fasting insulin, fructosamine, and glycated hemoglobin/A1c, respectively), and other glycemic parameters (GlycoMark, β-cell function, and insulin sensitivity/resistance) will be obtained. Lipid profile (total cholesterol, LDL, HDL, and triglycerides), inflammation (hs-CRP), progression to type 2 diabetes mellitus, as well as safety indices (ALT, AST) will be obtained. An intention-to-treat analysis will be used to assess changes in study outcomes. DISCUSSION: Treatment options for adults with prediabetes are currently limited. This study aims to evaluate the safety and efficacy of a commercially available dietary supplement in the popular, but as yet insufficiently studied, category of polyherbal formulas for the management of glycemic parameters and other biomarkers associated with prediabetes. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03388762 . Retrospectively registered on 4 January 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Feinberg T, Wieland LS, Miller LE, et al. Polyherbal dietary supplementation for prediabetic adults: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30616613. doi:10.1186/s13063-018-3032-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。